Onconetix (ONCO) Proxy Filing summary

Executive summary

• The proxy filing details an annual meeting to vote on key proposals, including director elections, equity plan amendments, a reverse stock split, preferred stock conversions, major share issuances, warrant exercises, auditor ratification, and potential adjournment to solicit more votes.

• The company recently acquired Proteomedix AG, making it a wholly owned subsidiary, and issued Series B Preferred Stock convertible into a significant majority of the post-conversion common stock, pending shareholder approval.

• The company is focused on commercializing Proclarix, a prostate cancer diagnostic, and has paused commercialization of ENTADFI due to financial constraints and is exploring strategic alternatives for that asset.

• The company faces substantial liquidity challenges, with a working capital deficit, accumulated losses, and a need to raise additional capital to continue operations beyond Q3 2024.

• A fairness opinion from H.C. Wainwright & Co. concluded the Proteomedix acquisition consideration was fair from a financial perspective.

Voting matters and shareholder proposals

• Election of two Class III directors for a three-year term.

• Amendment to the 2022 Equity Incentive Plan to increase the share reserve by 26,850,000 shares.

• Reverse stock split proposal at a ratio between 1-for-30 and 1-for-60 to regain Nasdaq compliance.

• Approval of conversion of Series A Preferred Stock into up to 5,709,935 shares of common stock.

• Approval of conversion of Series B Preferred Stock into 269,672,900 shares of common stock and related PMX Financing shares.

• Approval of issuance of up to 22,898,031 shares upon exercise of certain warrants.

• Ratification of EisnerAmper LLP as independent auditor for 2024.

• Approval to adjourn the meeting if necessary to solicit additional proxies.

Board of directors and corporate governance

• The board is currently composed of five members, with a mix of Onconetix and Proteomedix designees post-stockholder approval.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance, all with independent directors.

• The board recommends voting “FOR” all proposals.